FMD and Neoadjuvant Chemo-immunotherapy in TNBC

Inclusion Criteria: * Written informed consent obtained from the patient or their legal representative. * Good patient compliance, willing and able to adhere to the prescribed dietary intervention plan, visits, treatment schedule, laboratory tests, and other study procedures. * Female, aged 18 to 70 years. * ECOG performance status score of 0 to 1, with an expected survival of \>12 weeks. * Female patients of childbearing potential must agree to use reliable methods of contraception from before trial entry, throughout the study, and for 8 weeks after the completion of the study. * Patients with pathologically confirmed primary breast cancer, with a primary tumor ≥2 cm and regional lymph node status N0-N3 (AJCC Version 8); patients with positive lymph nodes may have a primary tumor of any size; no distant metastases (M0). * Triple-negative or near-triple-negative subtype, defined as HR-negative or low expression (ER and/or PR positivity rate 1%-10%) and HER2-negative (IHC 0, 1+, or 2+ with FISH-negative). * No prior history of any anti-tumor therapy, including chemotherapy, radiotherapy, and biological therapy. * Hemoglobin ≥90 g/L (can be maintained or exceed this level via transfusion). * Absolute neutrophil count ≥1.5 × 10E9/L. * Platelet count ≥100 × 10E9/L. * Total bilirubin ≤1.5 × upper limit of normal (ULN). * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5 × ULN. * Creatinine ≤1.5 × ULN. * Fasting blood glucose \<250 mg/dL (13.89 mmol/L). * Pr…